Homepage - Nimbus Therapeutics
2024年10月23日 · At Nimbus, exquisite selectivity is at the core of everything we do. From people to targets to molecules to partners, our meticulous choices enable us to successfully design and develop small molecule medicines capable of improving patients’ lives.
About - Nimbus Therapeutics
Our name, Nimbus, signifies a radiant light or luminosity, evoking the image of an aura of excellence, expertise, and achievement. We strive to embody this ideal every day as we work to illuminate the path from discovery to new medicines through our passionate team, multidisciplinary approach, and pioneering molecules.
Pipeline - Nimbus Therapeutics
cGAS (cyclic GMP-AMP synthase) is a component of the innate immune system that senses cytosolic dsDNA and initiates an inflammatory cascade. It is a key driver of inflammation in autoimmune and other diseases. cGAS activates the protein STING (stimulator of interferon genes), which propagates a pro-inflammatory response culminating in the activation of the …
Culture & Careers - Nimbus Therapeutics
Nimbus is a private company located in Boston, MA with a passionate, talented, multidisciplinary team of “Nimbi.” United by a shared mission to develop breakthrough medicines for patients through precision small molecule design, our people …
October 2024 - Nimbus Therapeutics
2024年10月23日 · The company is headquartered in Boston, Mass. To learn more about Nimbus, please visit www.nimbustx.com. Media Contact. Cindy Fung, PhD. Nimbus Therapeutics. [email protected]
Our Approach - Nimbus Therapeutics
The heart of our approach is using collaboration to assemble a powerful structure-based drug discovery engine. Our ‘special sauce’ is applying that engine and our unique collective expertise to drive target selection and the design of novel molecules that become breakthrough medicines.
Nimbus Therapeutics Presents First Preclinical Data on Novel WRN ...
2024年10月23日 · New development candidate, NTX-452, a non-covalent WRN inhibitor, demonstrated significant tumor regression and complete responses at low oral doses in MSI-H tumor models refractory to immunotherapy and chemotherapy
Nimbus Therapeutics Announces Expansion of Its Immunology …
2024年1月5日 · Nimbus’ pipeline includes a clinical-stage HPK1 inhibitor for the treatment of cancer (NCT05128487), as well as a diverse portfolio of preclinical programs focused on cancer, autoimmune conditions, and metabolic diseases. Nimbus is headquartered in Boston, Mass. To learn more about Nimbus, please visit www.nimbustx.com. Media Contact
Nimbus Therapeutics Presents New Positive Monotherapy Phase …
2024年5月23日 · Nimbus Therapeutics Presents New Positive Monotherapy Phase 1/2 Clinical Data of HPK1 Inhibitor in Treatment of Advanced Solid Tumors at 2024 ASCO Annual Meeting
Science - Nimbus Therapeutics
Nimbus is a “science first” biotech company. Our target selection process, one of our most crucial scientific endeavors, is driven by compelling evidence linking molecular targets to human disease pathology.